We are live on ! Find out more
CLDI icon

Calidi Biotherapeutics
CLDI

21 hedge funds and large institutions have $36.1M invested in Calidi Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 0 increasing their positions, 7 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.62% less ownership

Funds ownership: 0.75% → 0.13% (-0.62%)

50% less funds holding

Funds holding: 42 → 21 (-21)

70% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 30

82% less capital invested

Capital invested by funds: $204M → $36.1M (-$168M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 7

Holders
21
Holders Change
-21
Holders Change %
-50%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
–
Reduced
7
Closed
30
Calls
$597K
Puts
–
Net Calls
+$597K
Net Calls Change
-$5K

Top Buyers

Rank Fund Capital Flow
1
FTCM
First Trust Capital Management
Illinois
+$4M
2
SFM
Spartan Fund Management
Canada
+$1.5M
3
LSC
Logan Stone Capital
Illinois
+$1.49M
4
KL
KIM LLC
Kansas
+$999K
5
Citadel Advisors
Citadel Advisors
Florida
+$937K

Top Sellers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
-$18.2M
2
WP
Woodline Partners
California
-$15.8M
3
SCM
Shaolin Capital Management
Florida
-$12M
4
AMH
Apollo Management Holdings
New York
-$11.8M
5
Marshall Wace
Marshall Wace
United Kingdom
-$10.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
26
Aristeia Capital
Connecticut
– -$9.84M -8,250 Closed
PC
27
Periscope Capital
Ontario, Canada
– -$9.58M -8,034 Closed
Nomura Holdings
28
Nomura Holdings
Japan
– -$9.3M -7,797 Closed
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
– -$8.15M -6,834 Closed
SC
30
Sculptor Capital
New York
– -$7.6M -6,372 Closed
SCM
31
Saba Capital Management
New York
– -$6.18M -5,179 Closed
RCM
32
Radcliffe Capital Management
Pennsylvania
– -$3.98M -3,338 Closed
OCM
33
Oaktree Capital Management
California
– -$2.98M -2,500 Closed
Parallax Volatility Advisers
34
Parallax Volatility Advisers
California
– -$2.52M -2,117 Closed
WRBC
35
W.R. Berkley Corp
Connecticut
– -$2.34M -1,964 Closed
CC
36
Centiva Capital
New York
– -$1.99M -1,667 Closed
RL
37
RPO LLC
Connecticut
– -$1.73M -1,446 Closed
Blackstone Inc
38
Blackstone Inc
New York
– -$1.7M -1,424 Closed
Goldman Sachs
39
Goldman Sachs
New York
– -$1.26M -1,053 Closed
Bank of Montreal
40
Bank of Montreal
Ontario, Canada
– -$995 -833 Closed
Deutsche Bank
41
Deutsche Bank
Germany
– -$994K -833 Closed
BFM
42
Boothbay Fund Management
New York
– -$860K -721 Closed
LA
43
Linden Advisors
New York
– -$497K -417 Closed
SCM
44
Segantii Capital Management
Hong Kong
– -$497 -417 Closed
EC
45
Elequin Capital
New York
– -$398K -333 Closed
KKRC
46
Kohlberg Kravis Roberts & Co
New York
– -$351K -294 Closed
AI
47
Arena Investors
New York
– -$349K -293 Closed
PCM
48
Prelude Capital Management
New York
– -$322K -270 Closed
CCFM
49
Cohen & Co Financial Management
New York
– -$3K -265 Closed
SSA
50
Schonfeld Strategic Advisors
New York
– -$274K -229 Closed
1
2
3

CLDI Hedge Fund Activity: Q3 2022 in Review

21 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q3 2022, worth a combined $36.1M — down 82% from $204M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of CLDI and 9 opened new positions — a net loss of 21 holders — while 7 trimmed existing stakes and 0 added.

The largest buyer was First Trust Capital Management, opening a new position worth an estimated $4M. The largest seller was Polar Asset Management Partners, cutting an estimated $18.2M.

  • 21 institutional investors held Calidi Biotherapeutics (CLDI) as of Q3 2022, down from 42 in Q2 2022.
  • Funds reported $36.1M of Calidi Biotherapeutics stock for Q3 2022, down 82% quarter-over-quarter.
  • 9 funds opened new Calidi Biotherapeutics positions in Q3 2022 and 30 closed out, a net change of -21 holders.
  • The largest Calidi Biotherapeutics buyer in Q3 2022 was First Trust Capital Management, an estimated $4M added.
  • The largest Calidi Biotherapeutics seller in Q3 2022 was Polar Asset Management Partners, an estimated $18.2M sold.

Based on aggregated 13F filings for Q3 2022.